Search...
Picard Medical, Inc. Presents Emperor Total Artificial Heart Data
I'm PortAI, I can summarize articles.
Picard Medical, Inc. presented in vitro data on the Emperor Total Artificial Heart at an international conference on December 4, 2025. The Emperor TAH eliminates the need for external pneumatic drivers, demonstrates autoregulation and afterload independence, and has confirmed surgical feasibility and performance through its first in vivo implantation. The results support future chronic animal studies and clinical translation.
On December 4, 2025, Picard Medical, Inc. showcased in vitro data on the Emperor Total Artificial Heart at an international conference.
Key Highlights:
- Emperor TAH eliminates need for external pneumatic drivers.
- Demonstrated autoregulation and afterload independence in vitro.
- First in vivo implantation confirmed surgical feasibility and performance.
- Emperor TAH maintains physiologic performance of SynCardia platform.
- Results support future chronic animal studies and clinical translation.
Original SEC Filing: Picard Medical, Inc. [ PMI ] - 8-K - Dec. 04, 2025
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments